DATE: September 5, 2017
TIME: 8:00AM PT, 11:00AM ET
A recent report indicates that circa 79% of 483 warning letters issued by the FDA to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines their expectations for quality critical instrumentation in the GMP environment in their 21 CFR Part 11 ruling. This webinar takes a look at how quality-critical on-line Total Organic Carbon (TOC) and conductivity instrumentation can be configured to help companies comply with the FDA’s expectations on data integrity, including the use of Microsoft Active Directory and PDF data export.
Immunology
Clinical Diagnostics
Biotechnology
Laboratory Testing
Cancer Research
Molecular Biology
Molecular Diagnostics
Genetics
Clinical Research
Clinical Chemistry
Microbiology
Cell Biology
Infectious Disease
Cancer Diagnostics
Genomics
North America48%
Europe20%
Asia16%
South America5%
Africa3%
Website Visitors100%
Facility/Department Manager16%
Student11%
Executive11%
Engineer9%
QC/QA9%
Research Scientist8%
Medical Laboratory Technician6%
Marketing/Sales6%
Scientist5%
Consultant4%
Lab Management3%
Chemist3%
Medical Doctor/Specialist3%
Educator/Faculty3%
Clinical Laboratory Scientist2%
Microbiologist2%
Pharmaceutical Company4%
Biotech Company4%
Hospital3%
Clinical Laboratory3%
Academic Institution3%
Distribution/sales2%
Ambulatory Care2%
Life Science Company2%
Research Institute2%
Consultant1%
Independent Laboratories1%
Diagnostic Company1%
Manufacturer - Other1%
Industrial Company1%
Other3%